Loading clinical trials...

Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue

NCT01157650•Clinica Universidad de Navarra, Universidad de Navarra

View on ClinicalTrials.gov

Summary

Primary outcome measure: Evaluation of viability, security and tolerance of the adipose-derived mesenchymal stem cells implant (ASCs) in fistulizing Crohn's disease patients, collecting the reactions and adverse events occurred during the study. Secondary outcome measures: 1. Evaluating the Adipose-derived mesenchymal stem cells therapeutic effect, in particular: * Fistulas healing efficiency * Changes in quality of life in patients treated * Changes of systemic Crohn's disease after implant * Relapse rate monitored among patients who achieved Adipose-derived mesenchymal Stem Cells treatment success. 2. Achieving the biological characterization of the cell product used and its correlation with the therapeutic effect measured with: * Phenotype study * Suppressor capacity study. * Citoquines production analysis

Detailed Description

The aim of this study is to evaluate the role of Autologous Mesechymal Stem Cells derived from adipose tissue in the treatment of fistulous Crohn disease. 15 Crohn's disease patients with one or more enterocutaneous, recto-vaginal or complex perianal fistula, will be included. The trial is divided in three phases: I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature. Fistulous disease will be evaluated by MRI for perianal and rectovaginal fistulas, and by CT scan in the case of enterocutaneous fistula. Previous laboratory test and radiological studies are valid for evaluation if they were obtained within two and six months, respectively, prior to this evaluation, and in the absence of clinical changes. II.- Treatment phase includes: 1. Liposuction procedure to obtain adipose tissue. 2. Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs) 3. ASCs implant III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Fistulizing Crohn´s disease patients with 1 or more enterocutaneous fistulas, recto-vaginal fistula or complex perianal fistula. The complex perianal fistula is defined as a fistula presenting one of these conditions:
•* Trans-sphincteric, supra-sphincteric or extra-sphincteric tract, determined with:
•* Clinical criteria: No palpation of the tract and surgical exploration
•* Radiological criteria: Nucleal Magnetic Resonance (NMR)or Echoendoscopy
•* Multiple fistulas
•* "Horseshoe" fistula
•* Any fistula with fecal incontinence associated
•* Any fistula with a risk of fecal incontinence as a result of:
•* previous anal fistula surgery or other perianal pathology (hemorrhoids, fissures), that involves lesions or muscular complications.
•* Obstetric or iatrogenic sphincter lesions
+5 more criteria

Exclusion Criteria

•1. Patients with a highly active CD, i.e., if they meet any of the following criteria:
•* Presence of severe proctitis (prominent friability, spontaneous bleeding, multiple erosions, deep ulcers) or dominant active luminal disease that requires immediate treatment, revealed by rectosigmoidoscopy
•* CDAI ≥201
•2. Presence of abscess or other collections not drained (revealed by basal radiologic study).
•3. Presence of setons drainage, unless they are removed before treatment beginning.
•4. Rectal and/ or anal stenosis revealed with rectoscopy or EBA.
•5. Patients needs surgery in the perianal region for other reasons than fistulas at inclusion or within 26 weeks after treatment administration.
•6. Patients who have received infliximab or any other anti-TNF agent within 8 weeks before the cell treatment administration.
•7. Patients who have received tacrolimus or cyclosporine within 4 weeks before cell treatment.
•8. Patients with a history of alcohol or other addictive substances abuse within 6 months before inclusion.
+9 more criteria

Locations (3)

Clínica Universitaria de Navarra

Pamplona, Pamplona, Spain

Hospital Provincial de Navarra

Pamplona, Pamplona, Spain

Hospital Virgen del Camino

Pamplona, Pamplona, Spain

Key Dates

Start Date

June 1, 2010

Primary Completion Date

September 1, 2013

Completion Date

September 1, 2013

Last Updated

November 8, 2016

Enrollment

ACTUAL participants

Conditions

Crohn Disease

Interventions

Autologous mesenchymal stem cells

OTHER

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease)IBS - Irritable Bowel Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 8, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue

Inclusion Criteria

Exclusion Criteria

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Immunological Characteristics of Preclinical IBD

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study